Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The initial signs of Duchenne muscular dystrophy in a 3 or 4-year-old child may be subtle, explains Dr. Alexandra ...

Duchenne muscular dystrophy (DMD) is a genetic condition that primarily affects people assigned male at birth. However, due to the condition’s X-linked inheritance pattern, only people assigned ...

The mother of a teenage boy, with muscular dystrophy, said her son hasn’t been able to leave their Oakland home for almost a ...

The Phase I/II trial sought to establish the impact of DYNE-251 on mobility-related endpoints, seeing an increase over ...

Augustine Therapeutics has raised €78 million ($85 million) in first-round funding for a pipeline headed by a candidate for ...

Sarepta Therapeutics (SRPT) stock is reeling this week following the death of a 16-year-old patient treated with its flagship ...

After bringing Zolgensma to market in 2019 as the first gene therapy for spinal muscular atrophy, Novartis is back with an intrathecal formulation intended for older patients.

The competition between U.S. and Chinese biotech companies is particularly fierce in one field: CRISPR gene editing. Here are ...

Duchenne muscular dystrophy (DMD) is a rare neurological condition that causes severe muscle weakness and intellectual disability. DMD is an inherited (passed down) disorder. The condition is ...

Although cystic fibrosis is a single gene mutation, there are more than 1,000 different ways the CFTR gene can mutate in ...

Bipolar disorder is characterized by extreme mood swings, bouts of mania or hypomania, and episodes of depression.  It is a highly heritable and serious condition, that when untreated comes with a ...

Sarepta Therapeutics (SRPT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price ...